FDA Requests Zantac Be Pulled From the Market
Six months soon after unbiased tests first lifted the likelihood that popular heartburn drug ranitidine (Zantac) could possibly break down into the highly effective carcinogen n-nitrosodimethylamine (NDMA), the Fda has requested for the removal of all ranitidine products and solutions from the sector.
